Atrial Fibrillation (AFib) Management
Atrial fibrillation is the most common sustained cardiac arrhythmia, occurring in 1-2% of the general population. Its management has shifted significantly towards a holistic, structured approach.
1. Diagnosis & Confirmation
Clinical suspicion often arises from palpitation, dyspnea, or an irregularly irregular pulse on examination. However, ECG documentation is mandatory to establish the diagnosis.
- A standard 12-lead ECG showing AFib.
- A single-lead ECG tracing of ≥ 30 seconds showing AFib (e.g., from a Holter monitor, loop recorder, or validated smartwatch).
Key ECG Features: Absence of distinct P waves, replaced by rapid fibrillatory (f) waves, with an irregularly irregular RR interval.
2. The CC-ABC Pathway
The European Society of Cardiology (ESC) guidelines recommend the 'CC-ABC' pathway for streamlined management:
- C — Confirm AFib (12-lead ECG or ≥30s rhythm strip)
- C — Characterize AFib (the 4S-AF scheme: Stroke risk, Symptom severity, Severity of AF burden, Substrate)
- A — Anticoagulation / Avoid stroke (using CHA₂DS₂-VASc)
- B — Better symptom management (Rate vs. Rhythm control)
- C — Cardiovascular and Comorbidity optimization (Weight loss, BP control, sleep apnea treatment)
3. Anticoagulation (Avoid Stroke)
Stroke prevention is the most prognostic intervention in AFib management. DOACs (Direct Oral Anticoagulants) are recommended as first-line therapy over Vitamin K antagonists (warfarin) for non-valvular AFib.
| CHA₂DS₂-VASc Score | Recommendation (Men) | Recommendation (Women) |
|---|---|---|
| 0 | No antithrombotic therapy | - (A score of 1 in women is due to sex alone) |
| 1 | Consider OAC (Class IIa) | No antithrombotic therapy |
| 2 | OAC Recommended (Class I) | Consider OAC (Class IIa) |
| ≥ 3 | OAC Recommended (Class I) | OAC Recommended (Class I) |
Note: The HAS-BLED score should be calculated to identify modifiable bleeding risk factors, not to deny anticoagulation to patients at high stroke risk.
4. Rate vs. Rhythm Control
The EAST-AFNET 4 trial (2020) demonstrated that early rhythm control therapy (within 1 year of diagnosis) was associated with a lower risk of adverse cardiovascular outcomes compared to usual care (primarily rate control).
Rate Control
Target resting heart rate < 110 bpm (lenient control). Strict control (< 80 bpm) is reserved for patients who remain symptomatic on lenient control.
- 1st Line: Beta-blockers (e.g., Bisoprolol, Metoprolol) or Non-DHP Calcium Channel Blockers (Diltiazem, Verapamil).
- 2nd Line: Digoxin (useful in HFrEF) or combination therapy.
Rhythm Control
Preferred in younger patients, highly symptomatic patients, those with newly diagnosed AF, or AF secondary to a treated trigger (e.g., hyperthyroidism).
- Cardioversion: Electrical (DCCV) or Pharmacological (Flecainide, Amiodarone).
- Maintenance: Antiarrhythmic drugs (Class Ic, Class III) or Catheter Ablation (Pulmonary Vein Isolation).
5. Frequently Asked Questions
Do I need to bridge with heparin before starting a DOAC?
No. For outpatient initiation in stable patients, DOACs have a rapid onset of action (hours), eliminating the need for LMWH bridging that was historically required for warfarin.
Can I use aspirin instead of a DOAC for low-risk patients?
No. Antiplatelet monotherapy (Aspirin) is no longer recommended for stroke prevention in AFib. It is ineffective for AFib-related stroke and carries a similar bleeding risk to DOACs in the elderly.
References
- Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373-498.
- Kirchhof P, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4). N Engl J Med. 2020;383(14):1305-1316.
- January CT, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;140(2):e125-e151.